Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.
Remy NicolleJean-Baptiste BachetAlexandre HarléJuan Lucio IovannaPascal HammelVinciane ReboursAnthony TurpinMeher Ben AbdelghaniAlice C WeiEmmanuel MitryAnthony LopezJames J BiagiEric FrançoisPascal ArtruAurélien LambertDaniel J RenoufLaure MonardMarjorie MauduitNelson J DusettiThierry ConroyJerome CrosPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
This ancillary study of a phase III randomized trial demonstrates that among the quarter of patients with a GemPred-positive transcriptomic signature, survival was comparable with that of mFOLFIRINOX, whereas those receiving adjuvant gemcitabine had fewer adverse events.